BlossomHill Therapeutics is focused on developing innovative therapies for oncology and autoimmune diseases by leveraging a combination of human intelligence, creative thinking, and proven drug design expertise. The company aims to address significant challenges in cancer treatment, particularly the issues of on-target and off-target resistance that cancer cells develop against existing therapies. By rationally designing medicines that can counteract both known and potential resistance mechanisms, BlossomHill seeks to create more durable and effective treatments, ultimately striving to transform cancer from a terminal illness into a manageable condition.

The company is currently conducting clinical trials for its investigational drugs, including BH-30236, a multi-targeted CLK inhibitor for relapsed or refractory acute myeloid leukemia, and BH-30643, a mutant-selective OMNI-EGFR™ inhibitor designed to target resistance pathways in patients who no longer respond to traditional EGFR inhibitors. BlossomHill emphasizes the importance of clinical trials in advancing medical research and improving patient outcomes, while also providing pathways for expanded access to investigational drugs for patients who may not qualify for trials. Through these efforts, BlossomHill aims to enhance the quality of life for individuals living with cancer and autoimmune diseases.

United States

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.  The company is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D., and biotech business veteran, Y. Peter Li, Ph.D., M.B.A.  BlossomHill Therapeutics, Inc. is headquartered in San Diego, California.

BlossomHill Therapeutics

Company Details